Should we invest everything in biotech and pharma now?

Investor legend Warren Buffett enjoyed an ice cream at Berkshire Hathaway’s legendary annual general meeting in Ohama, Nebraska, in May 2017.
Image: Reuters

The search for the vaccine against the coronavirus is fueling the stock markets. Should investors now bet everything on biotech and pharmaceutical stocks? Better not, but they are worth a closer look. Warren Buffett shows us how.

A.bvie, Bristol-Meyers-Squibb Merck, Pfizer. Warren Buffett, the legendary American investor, has restructured his portfolio. The individual positions are relatively small, but when the “Oracle of Omaha”, as Buffett is also called, changes focus, investors around the world take notice. Buffett is not always right, but very rarely right wrong. The fact that Buffett is increasing in the pharmaceutical sector for the first time in years shows how much he too believes in the potential in the health sector. In any case, mayflies are not his thing.

When the Mainz vaccine manufacturer Biontech and Pfizer brightened the prospect of an approaching vaccine a good two weeks ago, there was euphoria on the stock market. The price of Biontech, whose shares are listed on the New York stock exchange Nasdaq, jumped from 91 to more than 105 dollars and made it to as much as 112 dollars in the further course of the day. Pfizer, the American pharmaceutical giant that does not do any research itself, but is in cooperation with the Mainz-based company and will make a significant contribution to sales, climbed by over 10 percent. The course developments of Deutsche Lufthansa and British Airways were almost more impressive. They shot up by a good 25 percent. Actually, it was expected that the markets would process the American elections, since Joe Biden had been declared the winner. But the vaccine was much more important to investors.


Related Articles

Back to top button